PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

Novel OTC formulation

Novel Formulation of a well-known US OTC Brand

Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC

Complex Injectable
(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma

ViePax® XR
(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules

Executive Team

The Dexcel family is made up of visionaries,

who understand how the pharmaceutical

industry influences our world and changes the

future for the better. We are always eager to

meet motivated people who share this vision

and wish to be part of our team.

Dan Oren
Founder, President & Chief Executive Officer

Dan Oren, founded Dexcel Pharma in 1968.

Mr. Oren has led the company since its inception for nearly five decades and continues to

serve as its CEO.

Mr. Oren is one of the pioneers of the Israeli pharmaceutical industry and is regarded as one

of the most appreciated industrial entrepreneurs in Israel.

Mr. Oren holds an MBA from the Tel Aviv university.

Ilan Oren
Vice President,
Business Development

Ilan Oren is Vice President, Business Development at Dexcel Pharma.

He was previously at L.E.K. Consulting, advising clients in the life science sector on corporate strategy, M&A, licensing and drug commercialization projects. 

Mr. Oren holds a B.A. in Economics from Harvard University.

Uri Oren
Vice President,
Chief Operating Officer

Uri Oren is Vice President, Chief Operating Officer at Dexcel Pharma.

He was previously at McKinsey & Company and has more than 10 years of experiences in the pharmaceutical industry serving in different roles. 

Mr. Oren holds an MBA from Columbia University.

Tomer Gold
Vice President,
Research & Development

Tomer Gold has served as Vice President of Research & Development at Dexcel Pharma since 2011. He oversees more than 120 scientists and engineers, with responsibilities in the development, registration and launching of the company’s generic and innovative products. Prior to joining Dexcel, Mr. Gold led the Pharmaceutical Development – European Union team of the Global Generic Research and Development Group at Teva Pharmaceuticals. Mr. Gold holds a BSc in Chemical Engineering and an MSc in Biomedical Engineering from the Technion-Israel Institute of Technology.

Yaron Erez
Vice President,
Finance and Chief Financial Officer

Yaron Erez joined Dexcel in 2018 as Vice President, Finance and CFO.

Mr. Erez brings to Dexcel 15 years of extensive international experience in the business sector, in finance management and M&A.

Prior to joining Dexcel, he served as Vice President for M&A and Strategy of Eden Springs Group HQ in Switzerland (Eden), leading more than 50 Mergers and Acquisitions across all of Europe and Israel. Prior to being named Vice President, he held several different positions at Eden including Finance Executive Director and the Group Business & Financial Controlling Director.

Mr. Erez is a CPA and holds a B.A. in Accounting and Economics (cum laude) and an MBA in Finance (magna cum laude) both from Tel Aviv University.

Ygal Seelenfreund
Vice President,
Sales & Marketing, International

Ygal Seelenfreund has been with Dexcel since 1996 and held various roles in the International sales and marketing. As Vice President for International Sales and Marketing since 2004, Mr. Seelenfreund oversees the promotion, marketing and sales of all Dexcel products outside of Israel, as well as customer relations, managing Dexcel’s subsidiaries and channel sales.

Mr. Seelenfreund holds a BA in Economics from the Hebrew University of Jerusalem.

Ran Kreshtino
Vice President,
General Manager, Dexcel Pharma Israel

Ran Kreshtino has been with Dexcel since 2000 and held various roles in sales and marketing.

As Vice President for Israel Sales and Marketing, Mr. Kreshtino oversees the promotion, marketing and sales of Dexcel products in Israel.

Mr. Kreshtino holds a BA in economics and management and MA in public policy.

Jonathan Grushka
Vice President, General Counsel

Mr. Grushka joined Dexcel in 2013 as General Counsel.

Prior to joining the company, Mr. Grushka was a partner in the law firm of Ron Gazit, Rotenberg & Co., where he specialized in commercial and corporate law, complex international transactions (including M&A and joint ventures), and licensing and distribution transactions of internationally prominent brands.

Mr. Grushka holds a LLB (cum laude) from the Hebrew University of Jerusalem and has been a member of the Israeli Bar Association since 2004.

Amit Rotem
Vice President,
Human Resources

Amit Rotem joined Dexcel in 2018 as Vice President of Human Resources. Ms. Rotem brings to Dexcel 20 years of extensive experience in human resource management, and previously held positions in Israel’s leading pharmaceutical, medical device and hi-tech companies.

Prior to joining the company, Ms. Rotem served as Senior Director Human Resources, R&D Israel for Teva Pharmaceuticals.

Ms. Rotem holds a BA in Sociology from Hebrew University and an M.A. Recanati Business School – Organizational Behavior from Tel Aviv University.